CEACAM1 and melanoma: Since CEACAM1 has been reported could inhibit cell proliferation, and cytotoxicity of T cells and NK cells in melanoma, a new anti-CEACAM1 antibody (MRG1) was used to bind to the N domain of CEACAM1, restoring the susceptibility of melanoma cells to attacked by T cells [133].